Conclusion
These preliminary data suggest that NOACs are as safe and effective
compared to VKA in patients with HCM undergoing catheter ablation for
AF.
Disclosures and Conflicts of Interest – AC has received
educational grants from Boston Scientific and Abbott; RJS has had
research agreements and speaker fees from Abbott, Medtronic, Boston
Scientific, and Biosense Webster; PDL has received educational grants
from Medtronic and Boston Scientific & is supported by UCL/UCLH
Biomedicine NIHR and Barts BRC; MF has received speaker fees from
Biotronik and Medtronic, and owns stocks of Epicardio ltd. All other
authors have reported that they have no relationships relevant to the
contents of this paper to disclose.